Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29488493 | 1.00 | HDAC3 (0.54) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL30108117 | 0.92 | CYP17A1 (0.55) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL26507051 | 0.92 | CYP17A1 (0.55) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL30632218 | 0.92 | CYP17A1 (0.55) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL20132007 | 0.90 | HDAC3 (0.58) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL25128584 | 0.89 | HDAC3 (0.48) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL30632219 | 0.88 | CYP17A1 (0.48) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL26507059 | 0.88 | CYP17A1 (0.48) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL30108127 | 0.88 | CYP17A1 (0.48) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL16960914 | 0.88 | HDAC3 (0.54) | HDAC3HDAC1HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900237-B2 | Sulfonamide compounds as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | claimed |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | Celera Corporation | 2003-08-21 | — | — | US | claimed |
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | claimed |
| WO-2003024923-A1 | SULFONAMIDE COMPOUNDS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-03-27 | — | — | WO | claimed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | claimed |
| EP-1159260-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | claimed |
| WO-2000055124-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | claimed |
| US-20260041781-A1 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12534474-B2 | Dihydrofuropyridine derivatives as rho-kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-01-27 | — | — | US | disclosed |
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | LILLY CO ELI (US) | 2025-11-20 | — | — | US | disclosed |
| US-12404298-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4587030-A2 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS AND IMMUNOCONJUGATES THEREOF | Adcentrx Therapeutics Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4263547-B1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2025-07-02 | — | — | EP | disclosed |
| US-20030220337-A1 | Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses | SAM-SUNG ELECTRONICS CO., LTD. (KR) | 2003-11-27 | — | — | US | disclosed |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | Celera Corporation | 2003-08-21 | — | — | US | disclosed |
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003024923-A1 | SULFONAMIDE COMPOUNDS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| EP-1159260-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000055124-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220337-A1 | Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses | GPX4, GPX1, LPO | HDAC3 2931/4885HDAC1 1754/4885HDAC2 1919/4885 |
| US-12404298-B2 | Glucocorticoid receptor agonists | NR3C1, NR3C2, MC2R | HDAC3 350/4885HDAC1 767/4885HDAC2 575/4885 |
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | HDAC3 350/4885HDAC1 767/4885HDAC2 575/4885 |
| US-12534474-B2 | Dihydrofuropyridine derivatives as rho-kinase inhibitors | ROCK1, RHOC, ROCK2 | HDAC3 918/4885HDAC1 1391/4885HDAC2 1860/4885 |
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | HDAC3 498/4885HDAC1 562/4885HDAC2 989/4885 |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | PRSS1, PRSS3, SPINT2 | HDAC3 434/4885HDAC1 538/4885HDAC2 502/4885 |
| US-20260041781-A1 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS AND IMMUNOCONJUGATES THEREOF | NR3C1, NR3C2, MC2R | HDAC3 652/4885HDAC1 1183/4885HDAC2 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.